What We're Reading: Page 226
Industry reads hand-picked by our editors
Oct 28, 2019
-
The Boston Globe
As his Alzheimer's looms, Charles and Pam Ogletree take one last walk in love
-
The Wall Street Journal
Intraparty Disputes Dim Outlook for Drug-Price Legislation
-
The New York Times
Scientists Were Hunting for the Next Ebola. Now the U.S. Has Cut Off Their Funding.
-
Bloomberg
Mylan CEO Bresch to Get $30.8 Million Payout After Pfizer Deal
Oct 25, 2019
-
Reuters
Biogen's secret campaign to bring its Alzheimer's drug back from the ashes
-
Kaiser Health News
Pharma sells states on ‘Netflix Model’ to wipe out hep C. But at what price?
-
Bloomberg
China's $132 billion market pushes big pharma into uncharted territory
-
San Francisco Business Times
As Stripe grabs big South San Francisco lease, biotech loses space to tech
Oct 24, 2019
Oct 23, 2019
-
Reuters
Johnson & Johnson CEO testified Baby Powder was safe 13 days before FDA bombshell
-
STAT
Alzheimer's patients in Biogen trial press for new access to treatment
-
Bloomberg
China Drugmaking Giant Says Cheap Meds Stymie Pharma's Future
-
The Wall Street Journal
Advice to Give Women Blood Thinners After C-Sections Draws Fire
Oct 22, 2019
Oct 21, 2019
-
Bloomberg
China Aims to Build Cheapest Healthcare With Lower Drug Prices
-
Financial Times
Neil Woodford: the inside story of his rise and dramatic fall
-
MIT Technology Review
The newest gene editor radically improves on CRISPR
Oct 18, 2019
-
Reuters
Judge's unorthodox approach has huge opioid settlement within reach
-
Bloomberg
House Democrats Push Forward With Drug-Price Negotiation Bill
-
ProPublica
We Found Over 700 Doctors Who Were Paid More Than a Million Dollars by Drug and Medical Device Companies
-
CBC News
Canadian breakthrough that became the world's most expensive drug, then vanished, gets second chance
Previous
